Tandem Diabetes Care Stock Alpha and Beta Analysis

TNDM Stock  USD 19.17  0.99  5.45%   
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Tandem Diabetes Care. It also helps investors analyze the systematic and unsystematic risks associated with investing in Tandem Diabetes over a specified time horizon. Remember, high Tandem Diabetes' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Tandem Diabetes' market risk premium analysis include:
Beta
0.82
Alpha
(0.50)
Risk
5.35
Sharpe Ratio
(0.14)
Expected Return
(0.76)
Please note that although Tandem Diabetes alpha is a measure of relative return and represented here as a single number, it indicates the percentage above or below your selected benchmark (i.e., Dow Jones Industrial index.) So in this particular case, Tandem Diabetes did 0.50  worse than the index. Remember, a high alpha is always good. Beta, on the other hand, measures the volatility (or risk) of an investment. It is an indication of Tandem Diabetes Care stock's relative risk over its benchmark. Tandem Diabetes Care has a beta of 0.82  . As returns on the market increase, Tandem Diabetes' returns are expected to increase less than the market. However, during the bear market, the loss of holding Tandem Diabetes is expected to be smaller as well. As of the 15th of March 2025, Enterprise Value is likely to grow to about 2.2 B, while Book Value Per Share is likely to drop 3.82.

Enterprise Value

2.15 Billion

Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
  
Check out Tandem Diabetes Backtesting, Tandem Diabetes Valuation, Tandem Diabetes Correlation, Tandem Diabetes Hype Analysis, Tandem Diabetes Volatility, Tandem Diabetes History and analyze Tandem Diabetes Performance.

Tandem Diabetes Market Premiums

Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Tandem Diabetes market risk premium is the additional return an investor will receive from holding Tandem Diabetes long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Tandem Diabetes. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Tandem Diabetes' performance over market.
α-0.5   β0.82

Tandem Diabetes expected buy-and-hold returns

Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Tandem Diabetes' Buy-and-hold return. Our buy-and-hold chart shows how Tandem Diabetes performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.

Tandem Diabetes Market Price Analysis

Market price analysis indicators help investors to evaluate how Tandem Diabetes stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Tandem Diabetes shares will generate the highest return on investment. By understating and applying Tandem Diabetes stock market price indicators, traders can identify Tandem Diabetes position entry and exit signals to maximize returns.

Tandem Diabetes Return and Market Media

The median price of Tandem Diabetes for the period between Sun, Dec 15, 2024 and Sat, Mar 15, 2025 is 35.0 with a coefficient of variation of 19.04. The daily time series for the period is distributed with a sample standard deviation of 6.16, arithmetic mean of 32.35, and mean deviation of 4.54. The Stock received a lot of media exposure during the period.
 Price Growth (%)  
       Timeline  
1
Ryoncil FDA Approval and Market Launch Highlighted at Tandem Transplantation Meetings
02/13/2025
2
Disposition of 595 shares by Rick Carpenter of Tandem Diabetes subject to Rule 16b-3
02/18/2025
3
Acquisition by Shannon Hansen of 531 shares of Tandem Diabetes subject to Rule 16b-3
02/21/2025
4
Tandem Raises USD 10M in its Pre-seed Round to Revolutionize Pet Healthcare
02/24/2025
5
Risen Achieves 30.99 percent Efficiency with HJT-Perovskite Tandem Solar Cells
02/26/2025
6
Q4 2024 Tandem Diabetes Care Inc Earnings Call Transcript
02/27/2025
7
Not Many Are Piling Into Tandem Diabetes Care, Inc. Stock Yet As It Plummets 40
02/28/2025
8
Tandem Diabetes Care Inc Stock Price Down 2.44 percent on Mar 3
03/03/2025
9
Advisor360 Introduces Tandem A CRM for Independent Financial Advisors
03/04/2025
10
Tandem Diabetes Care downgraded to Equal-weight on guidance concerns
03/05/2025
11
Acquisition by Kyrillos Jean-claude of 10538 shares of Tandem Diabetes at 18.1217 subject to Rule 16b-3
03/07/2025
12
Victory Capital Management Inc. Decreases Stock Position in Tandem Diabetes Care, Inc. - Defense World
03/12/2025

About Tandem Diabetes Beta and Alpha

For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Tandem or other stocks. Alpha measures the amount that position in Tandem Diabetes Care has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
 2022 2023 2024 2025 (projected)
Payables Turnover6.977.6610.078.12
Days Of Inventory On Hand104.47151.69121.18173.07

Tandem Diabetes Upcoming Company Events

As portrayed in its financial statements, the presentation of Tandem Diabetes' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Tandem Diabetes' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Tandem Diabetes' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Tandem Diabetes. Please utilize our Beneish M Score to check the likelihood of Tandem Diabetes' management manipulating its earnings.
21st of February 2024
Upcoming Quarterly Report
View
1st of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
21st of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Build Portfolio with Tandem Diabetes

Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.

Build Diversified Portfolios

Align your risk with return expectations

By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
When determining whether Tandem Diabetes Care is a strong investment it is important to analyze Tandem Diabetes' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Tandem Diabetes' future performance. For an informed investment choice regarding Tandem Stock, refer to the following important reports:
Tandem Diabetes technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Tandem Diabetes technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Tandem Diabetes trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...